Premium
Influence of maternal systemic lupus erythematosus on first‐trimester combined screening for chromosomal abnormalities
Author(s) -
Heinig J.,
Steinhard J.,
Schmitz R.,
Nofer J.R.,
Kiesel L.,
Klockenbusch W.
Publication year - 2007
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.1737
Subject(s) - medicine , trisomy , down syndrome , first trimester , obstetrics , pregnancy , fetus , retrospective cohort study , aneuploidy , second trimester , gynecology , chromosome , biology , biochemistry , genetics , psychiatry , gene
Objective To explore the effect of maternal systemic lupus erythematosus (SLE) on first‐trimester screening markers for Down syndrome. Methods A retrospective study was conducted on 1150 normal singleton fetuses that underwent first‐trimester combined screening for Down syndrome. Fetal delta nuchal translucency (NT), maternal serum PAPP‐A and free β‐hCG were compared between pregnancies with SLE ( n = 10) and without preexisting maternal disease ( n = 1140). Results The medians ± SD for delta NT, log 10 MoM of PAPP‐A and free β‐hCG ± SD in pregnancies with SLE and without maternal disease were − 0.18 ± 0.29 versus − 0.18 ± 0.33, 0.005 ± 0.32 versus 0.02 ± 0.26, and 0.22 ± 0.19 versus − 0.014 ± 0.28, with a p value of 0.7, 0.98 and 0.03, respectively. Conclusions Patients with preexisting SLE have increased maternal serum‐free β‐hCG levels in the first‐trimester. But, because of the multimodal procedure of risk calculation there is no significant difference in the screen‐positive rate after the combined first‐trimester screening for trisomy 21. Copyright © 2007 John Wiley & Sons, Ltd.